SEONGNAM, South Korea, July 29, 2024 /PRNewswire/ -- Bridge Biotherapeutics (KQ288330), a clinical-...
SEONGNAM, South Korea and ATLANTA, March 28, 2024 /PRNewswire/ -- Bridge Biotherapeutics (KQ288330)...
SEONGNAM, South Korea and AURORA, Colo., March 26, 2024 /PRNewswire/ -- Bridge Biotherapeutics (KQ2...
SEONGNAM, South Korea and NEWTON, Mass., Oct. 30, 2023 /PRNewswire/ -- Bridge Biotherapeutics (KQ28...
* The independent data monitoring committee (IDMC) recommended the continuation of the BBT-877 Ph...
Bridge to join as an industry member to advance the science of early detection and speed developmen...
SEONGNAM, South Korea and CAMBRIDGE, Mass., May 29, 2023 /PRNewswire/ -- Bridge Biotherapeutics Inc...
* The company has been notified by the FDA that the Phase 1/2 clinical trial may proceed * The ...
* New preclinical data validate anti-tumor efficacy and intracranial activity of the drug candida...
SEONGNAM, South Korea and CAMBRIDGE, Mass., April 12, 2023 /PRNewswire/ -- Bridge Biotherapeutics (...
* The abstract of BBT-207 preclinical studies is now available on the AACR
website
2023-03-15 21:00
2060
* BBT-401 meets safety endpoints achieved in previous clinical studies * The drug candidate did ...
SAN FRANCISCO and SEONGNAM, South Korea, Jan. 3, 2023 /PRNewswire/ -- Bridge Biotherapeutics (KQ288...
* Non-clinical studies explored the potent anti-fibrotic and anti-inflammatory efficacy of BBT-30...
* BBT-877 is intended to explore its treatment efficacy in idiopathic pulmonary fibrosis patients...
* The study confirmed preliminary efficacy and safety of BBT-176 along with its treatment respons...
* The abstract suggests that BBT-176 has shown its capability of inducing clinical tumor response...
SEONGNAM, South Korea, May 25, 2022 /PRNewswire/ -- Bridge Biotherapeutics Inc. (KQ288330), a South...
* Data analysis to explore demonstrated anti-tumor activity of BBT-176, a fourth generation EGFR ...
* The licensing deal includes an upfront payment of USD 1.63 million, and may reach up toUSD 24.4...